We have summarized here the results of prospective study demonstrating that up to 2 years of treatment with lurasidone in youth presenting with bipolar depression was generally safe and well tolerated, with a relatively low rate of study discontinuation, minimal impact on weight, metabolic parameters, and prolactin, and long-term improvement in depressive symptoms. The gene discussed is PRL; the disease is bipolar disorder.